Buy BioZapetite

BioZapetite delivers orforglipron (6 mg), a first-in-class oral, small-molecule GLP-1 receptor agonist designed for investigational use. Unlike peptide GLP-1 agonists, orforglipron is orally bioavailable without fasting or water restrictions and demonstrates robust pharmacology in glucose and weight regulation.

Together, its mechanisms are designed to:

• Promote glucose disposal & insulin sensitivity by enhancing glucose-dependent insulin secretion, suppressing glucagon, and improving post-prandial glucose control [1][3].
• Drive weight reduction & appetite control through central satiety signaling, slowed gastric emptying, and consistent reductions in caloric intake [1][2].
• Improve lipid & cardiometabolic health via secondary benefits of weight loss, including reductions in blood pressure, triglycerides, and waist circumference [1][3].
• Provide oral dosing convenience with a ~29–49 h half-life supporting once-daily use and no need for co-formulated absorption enhancers [4][6].
• Exhibit a safety profile consistent with injectable GLP-1 medicines, dominated by mild-to-moderate GI events during dose titration, with no hepatic safety signal in Phase 3 readouts [3][5].

These complementary mechanisms make BioZapetite a promising candidate for research in weight regulation, glycemic control, and cardiometabolic health.

BioZapetite Structure

Research Areas

• Appetite Regulation & Body Weight
• Glucose Disposal & Glycemic Control
• Cardiometabolic Risk Reduction
• Oral Small-Molecule Incretin Pharmacology

Translational Safety & GI Tolerability

Glucose Disposal & Glycemic Control

In a 26-week multicentre trial in type 2 diabetes (n=383), orforglipron reduced HbA1c up to –2.10% and body weight by –10.1 kg, significantly outperforming placebo and matching/exceeding dulaglutide at higher doses [3]. A 12-week Phase 1b trial reported HbA1c reductions of –1.5% to –1.8% with up to –5.8 kg weight loss [4].

Appetite & Weight Regulation

In a 36-week obesity study, orforglipron produced –9.4% to –14.7% weight reduction vs –2.3% with placebo, with 46–75% of participants achieving ≥10% weight loss depending on dose [1][2]. Improvements were observed in all prespecified cardiometabolic measures, including waist circumference, blood pressure, and lipid markers.

Oral Pharmacology & PK

Unlike oral peptide GLP-1 formulations, orforglipron does not require an absorption enhancer or fasting. AUC and Cmax decrease ~18–24% with food, but this is not clinically significant [6]. Half-life ~29–49 h supports once-daily dosing [4].

Safety & Tolerability

Across Phase 2 and Phase 3 programs, the safety profile was consistent with injectable GLP-1 RAs. GI events (nausea, diarrhea, dyspepsia, vomiting) were most common and dose-related, occurring mainly during titration [3][5]. In Phase 3 (ACHIEVE-1), discontinuations due to AEs were 4–8% vs 1% with placebo, and no hepatic safety signals were detected [5].

References

1. Wharton S, et al. NEJM 2023. Orforglipron in obesity: –9.4% to –14.7% weight loss at 36 weeks; improvements in cardiometabolic measures. https://pubmed.ncbi.nlm.nih.gov/37351564/
2. Wharton S, et al. NEJM 2023. Dose-dependent weight loss (–8.6% to –12.6% at 26 weeks) in obesity without diabetes. https://pubmed.ncbi.nlm.nih.gov/37351564/
3. Frias JP, et al. Lancet 2023. Phase 2 T2D: HbA1c ↓ up to –2.10%; weight ↓ up to –10.1 kg; greater efficacy than dulaglutide at high dose. https://cardiometabolicforum.com/publications/99
4. Pratt E, et al. Diabetes Obes Metab 2023. Phase 1b: HbA1c –1.5% to –1.8%, weight loss –5.8 kg; t½ ~29–49 h. https://pubmed.ncbi.nlm.nih.gov/37264711/
5. Lilly Press Release 2025. Phase 3 ACHIEVE-1: HbA1c ↓ –1.3% to –1.6%; weight ↓ –7.9%; GI AEs dose-related; no hepatic signal. https://www.prnewswire.com/news-releases/lillys-oral-glp-1-orforglipron-demonstrated-statistically-significant-efficacy-results-and-a-safety-profile-consistent-with-injectable-glp-1-medicines-in-successful-phase-3-trial-302430985.html
6. Ma X, et al. Diabetes Therapy 2024. Food-effect PK: AUC/Cmax ↓ ~18–24% fed vs fasted; overall well-tolerated; no SAEs. https://link.springer.com/article/10.1007/s13300-024-01554-1

Note: BioZapetite is supplied strictly for investigational research use only. It is not approved or intended for diagnostic, therapeutic, or in vivo applications in humans or animals.

Orforglipron (BioZapetite)

×

Disclaimer: For Research Purposes Only

This content is provided strictly for research purposes and does not constitute an endorsement or recommendation for the non-laboratory application or improper handling of peptides designed for research. The information, including discussions about specific peptides and their researched benefits, is presented for informational purposes only and must not be construed as health, clinical, or legal guidance, nor an encouragement for non-research use in humans. Peptides described here are solely for use in structured scientific study by authorized individuals. We advise consulting with research experts, medical practitioners, or legal counsel prior to any decisions about obtaining or utilizing these peptides. The expectation of responsible, ethical utilization of this information for legitimate investigative and scholarly objectives is paramount. This notice is dynamic and governs all provided content on research peptides. . .